Video content above is prompted by the following: What are the main unmet needs for recurrent C difficile infections and how do you see the field evolving in the future?

LPOXY’s plan is to take Sidiprev into a phase 2 study in hospitalized patients with Clostridioides difficile infection. Known as one of the superbugs that resists most antibiotics, C.

How does recurrent C difficile infection impact health care resources utilization and other medical costs? What are the ways in which recurrent C difficile infection can adversely impact a patient ...

The best rookies in sports history, from "Big Three" to "Big Two," dispatch from Paris, "The Diff," photo finish, and more.

Roche has obtained U.S. government green lights allowing its point-of-care testing system to be used to screen for multiple ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver ...

The major objective of this research collaboration is to develop new therapeutic drug candidates which target antimicrobial resistant pathogens. This work will utilize the Immuron technology platform, ...

Pfizer has been working on a potential vaccine for C. diff, but its first attempt missed ... updated formulation through mid-stage clinical testing. In the phase 3 ECOSPOR trial, patients who ...

Basel: Roche has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance and Clinical ...